Yeming Wang to China
This is a "connection" page, showing publications Yeming Wang has written about China.
Connection Strength
0.141
-
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020 May 24; 21(1):422.
Score: 0.031
-
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 05 16; 395(10236):1569-1578.
Score: 0.031
-
Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. Clin Infect Dis. 2021 05 18; 72(10):e545-e551.
Score: 0.008
-
The characteristics of laboratory tests at admission and the risk factors for adverse clinical outcomes of severe and critical COVID-19 patients. BMC Infect Dis. 2021 Apr 20; 21(1):371.
Score: 0.008
-
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 01 16; 397(10270):220-232.
Score: 0.008
-
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect. 2021 Jan; 27(1):112-117.
Score: 0.008
-
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 09; 56(3).
Score: 0.008
-
Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. Eur Respir Rev. 2020 Sep 30; 29(157).
Score: 0.008
-
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med. 2020 Oct; 14(5):601-612.
Score: 0.008
-
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 03 28; 395(10229):1054-1062.
Score: 0.008
-
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 02 15; 395(10223):497-506.
Score: 0.008
-
Comparison of the Cepheid Xpert Xpress Flu/RSV assay and commercial real-time PCR for the detection of influenza A and influenza B in a prospective cohort from China. Int J Infect Dis. 2019 Mar; 80:92-97.
Score: 0.007